| Patients who met
80-80 rule |
Total |
PEG-IFN alfa-2a |
PEG-IFN alfa- 2b |
P* |
| Genotype 1, n (%) |
286 |
171 (59.8) |
115 (40.2) |
0.45 |
| Age, years† |
49 ± 11 |
48 ± 11 |
49 ± 11 |
0.52 |
| Gender (male), n (%) |
186 (65.0) |
112 (65.5) |
74 (64.3) |
0.90 |
| BMI (Kg/m2)† |
24.6 ± 3.1 |
24.8 ± 3.2 |
24.3 ± 2.9 |
0.29 |
| ALT (IU/L) † |
100 ± 81 |
103 ± 80 |
97 ± 84 |
0.51 |
| HCV RNA (IU/mL) † |
3.7×106±1.6×106 |
2.4×106±1.5×106 |
5.6×106±2.2×106 |
0.15 |
| F3-4 Fibrosis stage, n (%)§ |
29/94 (30.9) |
26/75 (34.7) |
3/19 (15.8) |
0.17 |
| Genotype 2/3, n (%) |
185 |
107 (57.8) |
78 (42.2) |
|
| Age, years† |
49 ± 12 |
48 ± 12 |
50 ± 11 |
0.16 |
| Gender (male), n (%) |
108 (58.4) |
162 (61.8) |
108 (62.1) |
0.96 |
| BMI (Kg/m2) † |
23.9 ± 2.7 |
24.3 ± 3.1 |
23.6 ± 2.4 |
0.16 |
| ALT (IU/L) † |
97 ± 94 |
101 ± 88 |
94 ± 88 |
0.51 |
| HCV RNA (IU/mL) † |
1.8×106±1.5×106 |
1.6×106±1.2×106 |
2.1×106±1.4×106 |
0.49 |
| F3-4 Fibrosis stage, n (%)‡ |
11/63 (17.5) |
7/51 (13.7) |
4/12 (33.3) |
0.19 |
| Genotype others, n (%) |
9 (1.9) |
6 (2.1) |
3 (1.5) |
|
| Propensity score matched patients |
Total |
PEG-IFN alfa-2a |
PEG-IFN alfa- 2b |
P* |
| Genotype 1, n (%) |
248 |
124 |
124 |
0.45 |
| Age, years† |
50 ± 11 |
51 ± 11 |
50 ± 11 |
0.43 |
| Gender (male), n (%) |
148 (59.7) |
112 (65.5) |
74 (64.3) |
0.90 |
| BMI (Kg/m2) † |
24.4 ± 3.2 |
24.7 ± 3.2 |
24.3 ± 3.3 |
0.38 |
| ALT (IU/L) † |
93 ± 76 |
95 ± 74 |
92 ± 79 |
0.83 |
| HCV RNA (IU/mL) † |
3.0×106 ± 1.3×106 |
2.5×106 ± 1.3×106 |
3.6×106 ± 1.1×106 |
0.31 |
| F3-4 Fibrosis stage, n (%)# |
22/73 (30.1) |
18/50 (36.0) |
4/23 (18.2) |
0.17 |
| Genotype 2/3, n (%) |
150 |
75 |
75 |
|
| Age, years† |
50 ± 11 |
48 ± 12 |
50 ± 11 |
0.16 |
| Gender (male), n (%) |
81 (54.0) |
162 (61.8) |
108 (62.1) |
0.96 |
| BMI (Kg/m2) † |
23.9 ± 2.9 |
24.3 ± 3.1 |
23.6 ± 2.4 |
0.16 |
| ALT (IU/L) † |
89 ± 76 |
101 ± 88 |
94 ± 88 |
0.51 |
| HCV RNA (IU/mL) † |
1.7×106 ± 1.4×106 |
1.6×106 ± 1.2×106 |
2.1×106 ± 1.4×106 |
0.49 |
| F3-4 Fibrosis stage, n (%)￥ |
10/46 (21.7) |
6/34 (17.6) |
4/12 (33.3) |
0.42 |
Abbreviation
HCV - Hepatitis C Virus; BMI - Body Mass Index; ALT - Alanine Aminotransferase; PEG-IFN - Peginterferon
*P-value for difference between the PEG-IFN alfa-2a and PEG-IFN alfa-2b groups
†mean ± standard deviation
§, ‡ Data were available only in 94 and 63 patients, respectively
#,￥Data were available only in 73 and 46 patients, respectively |
